Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1153 details
Primary information
ID1661
ThPP IDTh1153
Therapeutic Peptide/Protein NameAlefacept
SequenceHeavy Chain: CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVA view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight51801.1
Chemical FormulaC2306H3594N610O694S26
Isoelectric Point7.86
Hydrophobicity-0.432
Melting Point (℃)N.A.
Half Life270 hrs
DescriptionImmunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Indication/DiseaseAs an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
PharmacodynamicsInterferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.
Mechanism of ActionInhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.
ToxicityWhile it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk.
MetabolismN.A.
AbsorptionBioavailability after IM administration is 63%.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesDermatologic and Immunosupressive agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionCanakinumab, Rilonacept- Increases immunosupressive effects
TargetT-cell surface antigen CD2, Complement C1r subcomponent, Complement C1q subcomponent subunit A, B, C, Low affinity immunoglobulin gamma Fc region receptor III-A,III-B, II-a, II-b, II-c
Information of corresponding available drug in the market
Brand NameAmevive
CompanyAstellas Pharma Inc.
Brand DiscriptionAMEVIVE (alefacept) is a CD2-directed LFA-3/Fc fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgGl. Alefacept is produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) mammalian cell expression system. The molecular weight of alefacept is 91.4 kilodaltons.
Prescribed forAMEVIVE is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Chemical NameN.A.
FormulationIt contains alefacept (15 mg), citric acid monohydrate (0.06 mg), glycine (5 mg), sodium citrate dehydrate (3.6 mg), and sucrose (12.5 mg) per 0.5 mL of reconstituted solution.
Physcial AppearanceAMEVIVE is supplied as a sterile, white-to-off-white, preservative-free, lyophilized powder
Route of AdministrationIntramuscular Injection
Recommended DosageThe recommended dose of AMEVIVE® is 15 mg intramuscularly once weekly for 12 weeks. The CD4+ T lymphocyte counts should be measured before initiating dosing.
ContraindicationAMEVIVE should not be administered to patients infected with HIV. AMEVIVE reduces CD4+ T lymphocyte counts, which might accelerate disease progression or increase complications of disease in these patients
Side EffectsLymphopenia, Malignancies, Serious Infections reuiring hospitalization, Hypersenstivity reactions.
Useful Linkhttp://www.rxlist.com/amevive-drug.htm
PubMed ID16865867, 16713481
3-D StructureTh1153 (View) or (Download)